Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

HitGen Delivers Candidates to Cedilla for Cancer Caused by Protein Dysregulation

publication date: Dec 2, 2020

Chengdu's HitGen announced its discovery collaboration with US-based Cedilla Therapeutics successfully identified small molecule candidates for cancer and other diseases caused by protein dysregulation. HitGen applied its large-scale target libraries to discover compounds that met Cedilla's specified criteria. Cedilla received an exclusive license to these compounds plus IP for further development and commercialization. HitGen will be eligible for future milestone payments and sublicensing income from Cedilla, in addition to research payments and an upfront license fee. More details....

Stock Symbol: (SHA: 688222)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital